Combining Curcumin (Diferuloylmethane) and Heat Shock Protein Inhibition for Neurofibromatosis 2 Treatment: Analysis of Response and Resistance Pathways

被引:31
作者
Angelo, Laura S.
Wu, Ji Yuan
Meng, Feng
Sun, Michael
Kopetz, Scott [2 ]
McCutcheon, Ian E. [3 ,5 ]
Slopis, John M. [4 ,5 ]
Kurzrock, Razelle [1 ,5 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Unit 455, Phase Program 1, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Neuro Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Neurofibromatosis Working Grp, Div Canc Med, Houston, TX 77030 USA
关键词
NF2; TUMOR-SUPPRESSOR; KAPPA-B KINASE; CANCER-CELLS; LIPOSOMAL CURCUMIN; PANCREATIC-CANCER; DRUG-COMBINATION; CLINICAL-TRIALS; IN-VIVO; APOPTOSIS; MERLIN;
D O I
10.1158/1535-7163.MCT-11-0243
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neurofibromatosis type 2 (NF2) is a genetic condition characterized by inactivation of the NF2 tumor suppressor gene and the development of schwannomas. The NF2 gene product, merlin, is activated (dephosphorylated) by contact inhibition and promotes growth suppression. We investigated the effect of curcumin (diferuloylmethane), a molecule with anti-inflammatory and antitumorigenic properties, on human schwannoma cell growth and the regulation of merlin by curcumin in both NF2 cells and neuroblastoma (non-NF2) cells. Curcumin inhibited the growth of HEI-193 schwannoma cells in vitro and downregulated the phosphorylation of Akt and extracellular signal-regulated kinase 1/2. Curcumin also activated MYPT1-pp1 delta (a merlin phosphatase), which was associated with dephosphorylation of merlin on serine 518, an event that results in the folding of merlin to its active conformation. In addition, curcumin induced apoptosis and generated reactive oxygen species in HEI-193 cells. Consequently, hsp70 was upregulated at the mRNA and protein levels, possibly serving as a mechanism of escape from curcumin-induced apoptosis and growth inhibition. Endogenous merlin and hsp70 proteins interacted in HEI-193 schwannoma and SK-N-AS neuroblastoma cells. The combination of curcumin and an hsp inhibitor synergistically suppressed schwannoma cell growth. Our results provide a rationale for combining curcumin and KNK437 in the treatment of NF2. Mol Cancer Ther; 10(11); 2094-103. (C) 2011 AACR.
引用
收藏
页码:2094 / 2103
页数:10
相关论文
共 52 条
[1]   Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IκBα kinase and Akt activation [J].
Aggarwal, S ;
Ichikawa, H ;
Takada, Y ;
Sandur, SK ;
Shishodia, S ;
Aggarwal, BB .
MOLECULAR PHARMACOLOGY, 2006, 69 (01) :195-206
[2]   Neurofibromatosis type 2 [J].
Asthagiri, Ashok R. ;
Parry, Dilys M. ;
Butman, John A. ;
Kim, H. Jeffrey ;
Tsilou, Ekaterini T. ;
Zhuang, Zhengping ;
Lonser, Russell R. .
LANCET, 2009, 373 (9679) :1974-1986
[3]   Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts [J].
Chang, LS ;
Akhmametyeva, EM ;
Wu, Y ;
Zhu, LY ;
Welling, DB .
GENOMICS, 2002, 79 (01) :63-76
[4]   Encapsulation and Sustained Release of Curcumin using Superparamagnetic Silica Reservoirs [J].
Chin, Suk Fun ;
Iyer, K. Swaminathan ;
Saunders, Martin ;
St Pierre, Tim G. ;
Buckley, Craig ;
Paskevicius, Mark ;
Raston, Colin L. .
CHEMISTRY-A EUROPEAN JOURNAL, 2009, 15 (23) :5661-5665
[5]   Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].
Chou, Ting-Chao .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681
[6]   Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method [J].
Chou, Ting-Chao .
CANCER RESEARCH, 2010, 70 (02) :440-446
[7]  
Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]
[8]   Phase II trial of curcumin in patients with advanced pancreatic cancer [J].
Dhillon, Navneet ;
Aggarwal, Bharat B. ;
Newman, Robert A. ;
Wolff, Robert A. ;
Kunnumakkara, Ajaikumar B. ;
Abbruzzese, James L. ;
Ng, Chaan S. ;
Badmaev, Vladimir ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4491-4499
[9]   Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service [J].
Evans, D. G. ;
Howard, E. ;
Giblin, C. ;
Clancy, T. ;
Spencer, H. ;
Huson, S. M. ;
Lalloo, F. .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (02) :327-332
[10]   Consensus Recommendations to Accelerate Clinical Trials for Neurofibromatosis Type 2 [J].
Evans, D. Gareth ;
Kalamarides, Michel ;
Hunter-Schaedle, Kim ;
Blakeley, Jaishri ;
Allen, Jeffrey ;
Babovic-Vuskanovic, Dusica ;
Belzberg, Allan ;
Bollag, Gideon ;
Chen, Ruihong ;
DiTomaso, Emmanuelle ;
Golfinos, John ;
Harris, Gordon ;
Jacob, Abraham ;
Kalpana, Ganjam ;
Karajannis, Matthias ;
Korf, Bruce ;
Kurzrock, Razelle ;
Law, Meng ;
McClatchey, Andrea ;
Packer, Roger ;
Roehm, Pamela ;
Rubenstein, Allan ;
Slattery, William, III ;
Tonsgard, James H. ;
Welling, D. Bradley ;
Widemann, Brigitte ;
Yohay, Kaleb ;
Giovannini, Marco .
CLINICAL CANCER RESEARCH, 2009, 15 (16) :5032-5039